All In Biotech

Drug Trial Radar · NCT06060665

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

IDEAL: A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)

Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

96

Actual

Start

Sep 5, 2023

Primary completion

May 6, 2026

Study completion May 6, 2026

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Sep 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA). The primary objective is to evaluate the effect of seladelpar treatment at Week 52 compared to placebo based on normalization of alkaline phosphatase (ALP) defined by a composite endpoint of ALP ≤ 1.0× upper limit of normal (ULN) and ≥ 15% decrease from baseline in PBC participants with an ALP value greater than ULN but less than 1.67× ULN.

Conditions

  • Primary Biliary Cholangitis

Interventions

  • Seladelpar 10 mgDrug

    Administered orally

  • PlaceboDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Response defined as Alkaline phosphatase (ALP) ≤ 1.0× Upper Limit of Normal (ULN) AND ≥ 15% Decrease in ALP at Week 52.Time frame: 52 weeks
  2. Type, Frequency, and Severity of Treatment-emergent Adverse Events.Time frame: 52 weeks

Locations

45 sites in 2 countries. Site status is shown where the registry gives one.

  • The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health

    Chandler, Arizona

  • California Liver Research Institute

    Pasadena, California

  • University of California (UC) Davis Medical Center

    Sacramento, California

  • California Pacific Medical Center

    San Francisco, California

  • University of Colorado Denver - School of Medicine - Anschutz Medical Campus

    Aurora, Colorado

  • South Denver Gastroenterology

    Englewood, Colorado

  • Florida Research Institute

    Lakewood Rch, Florida

  • University of Miami - Schiff Center for Liver Diseases

    Miami, Florida

  • Gastro Health Research

    Miami, Florida

  • Covenant Metabolic Specialists, LLC

    Sarasota, Florida

  • Covenant Metabolic Specialists, LLC

    Tampa, Florida

  • Digestive Healthcare of Georgia

    Atlanta, Georgia

  • Northwestern Medicine Clinical Research Unit (CRU)

    Chicago, Illinois

  • Tulane University Medical Center

    New Orleans, Louisiana

  • Louisiana Research Center, LLC

    Shreveport, Louisiana

  • Mercy Medical Center - Baltimore, Maryland

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Henry Ford Health System

    Novi, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Kansas City Research Institute

    Kansas City, Missouri

  • New-York-Presbyterian Brooklyn Methodist Hospital

    Brooklyn, New York

  • Northwell Health Center for Liver Disease and Transplantation

    Manhasset, New York

  • New York University (NYU) Langone Medical Center

    New York, New York

  • Weill Cornell Medicine

    New York, New York

  • University of Rochester Medical Center - Strong Memorial Hospital

    Rochester, New York

  • Gastro Health Research

    Liberty Township, Ohio

  • Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • UPMC Center for Liver Health

    Pittsburgh, Pennsylvania

  • OGI - Gastro One

    Cordova, Tennessee

  • Galen Hepatology

    Hixson, Tennessee

  • Gastrointestinal Associates of Northeast Tennessee, P.C.

    Johnson City, Tennessee

  • American Research Corporation - San Antonio, TX

    Austin, Texas

  • The Liver Institute at Methodist Dallas Medical Center

    Dallas, Texas

  • Liver Center of Texas

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Soma Clinical Trials, LLC

    Denison, Texas

  • Baylor College of Medicine - Baylor Clinic

    Houston, Texas

  • Liver Associates of Texas, P.A.

    Houston, Texas

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.